



Quanta Announces Poster Presentation at ASN Kidney Week 2019

Alcester, Warwickshire, UK, 04 November 2019: Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a pioneering British medical technology company developing a personal haemodialysis system (SC+) for patient use at home and in the clinic, announces that the Company will be presenting a poster at the ASN conference, reporting on results from an experimental pulsatile push–pull flow mechanism. These results demonstrate feasibility of using a small and easy-to-use haemodialysis system like SC+ to deliver enhanced solute clearance comparable to hemodiafiltration without any added complexity. The American Society of Nephrology (ASN) Kidney Week 2019 is being held November 5–10, 2019, in Washington DC.

Poster Presentation:

Title: Enhancement of Solute Clearance Using Experimental Pulsatile Push–Pull Dialysate Flow for the Quanta SC+: A Personal Clinic-to-Home Haemodialysis System

Abstract: SA-PO1076

Session: Home Hemodialysis

Location: Exhibit Hall, Walter E. Washington Convention Center

Date & Time: Saturday, 9th November 2019, 10:00 a.m. – 12:00 p.m. ET

The full poster will be available to view after the presentation on Quanta’s website: www.quantadt.com

If you would like to arrange a meeting with John E. Milad, Chief Executive Officer or Dr. Paul Komenda, Chief Medical Officer, please contact enquiries@quantadt.com

-ENDS-

For more information about Quanta, please contact:

Quanta

John E. Milad,
Chief Executive Officer

T: +44 (0)1789 400043
E: enquiries@quantadt.com

Consilium Strategic Communications

Amber Fennell / Matthew Neal / Lindsey Neville

T: +44 (0)203 709 5708
E: quanta@consilium-comms.com

About SC+

SC+ is a small, simple and powerful haemodialysis system designed to provide greater flexibility around where, when and how patients manage and receive their dialysis therapy. As a CE marked medical device, SC+ has been successfully piloted with the NHS, demonstrating clinical efficacy and performance compatible with traditional treatment regimens used in-centre. The innovative and patented technology behind SC+ is based on a design breakthrough that allows all dialysate fluid management to be conducted on a small, lightweight, disposable cartridge. The small form factor and simple-to-use design are intended to enable a broader range of users—including patients themselves—to manage dialysis therapy delivery across a wide range of settings—from the clinic to the home.

About Quanta

UK-based Quanta Dialysis Technologies aims to improve the lives of dialysis patients through innovation. Quanta's lead product SC+ is designed to empower dialysis patients by giving them greater flexibility, convenience and control over the delivery of their life-sustaining renal replacement therapy. The company has attracted funding from a group of leading investors that includes Wellington Partners, Seroba Life Sciences and b-to-v Partners.

For more information, please visit: www.quantadt.com